

Meeting Title: End of Life Care Committee Meeting

Date: June 5, 2026

Time: 1:00PM—3:00PM

Location / Platform: Online Teams

Committee Chair: Lawrence Leeman, MD, MPH

Note Taker: Leslie Peterson, NMDOH Medical Psilocybin Program

Important Reminder:

This meeting was recorded. For specific details pertaining to the meeting, please refer to the recording located on the Medical Psilocybin Advisory Board Website @ [https://www.nmhealth.org/about/mcpp/Medical Psilocybin Program/mpab/](https://www.nmhealth.org/about/mcpp/Medical%20Psilocybin%20Program/mpab/)

Attendees:

End of Life Care Committee Chair: Lawrence Leeman, MD, MPH

Department of Health Staff:

Dominick Zurlo
Brenda Martinez
Robert Truckner, MD
Jonathan Mouchet
Jorge Gonzales
Cyrus Rautman
Leslie Peterson
Raymond Gallegos
Cathy Augeri

Participants and Public Attendees:

Jim Dodson
Kate Hawke
Gregory Evans
Lida Fatemi, DO, MPH
Hanifa Nayo Washington
Catherine Sanchez, WCA
James Brown, Pharm.D, RPH, IDSP
Barak Wolff
Ellen Schimmels
Chris Caldwell
Jamie Beachy
Anne Marie M. Rodewald
Jennifer Johnson
Shaina Fawn
Senator Jeff Steinborn
Ian Dunn

Brooke Kaemingk
Joel Rosen, MD
Skye Rivers
Soma Franks
Jenn Clemente

1. Call to Order

- At 1:03PM the meeting was called to order by Jorge Gonzales.
- Jorge opened the meeting and reminded attendees of proper public meeting etiquette and the public meeting being recorded and publicly posted.
- Introductions: Participants introduced themselves and shared affiliations and geographic locations.

2. Approval of Prior Minutes

- Approved as submitted

3. Agenda Items and Discussion Summary

- A. July 10, 2026, tentative presentation from NYU End-of-Life Studies.
- B. Pharmacy Presentation by James Brown with regard to End-of-Life Care
 - a. 5 Degrees North Healing Foundation
 - b. How Psilocybin Works in the Brain
 - c. Drug-Drug Interactions
 - d. Pharmacokinetic Changes in the Elderly
 - e. Practical Applications for Facilitators
 - f. Examples of Drug Interactions
 - g. Serotonin Syndrome, a rare risk usually encountered with poly pharmacy
 - h. HPPD hallucinogen persisting perception disorder very rare
 - i. Management of Serotonin Syndrome
 - j. Psilocybin and psilocin in Parkinson's Disease
- C. EOL Committee: Scopes for End-of-Life Care Criteria
 - a. Establish definitions and scope for EOLC Criteria
 - b. EOL criteria eligibility for psilocybin assisted therapy
 - c. Prioritization guidelines for Equity Fund for EOL Care
 - d. Reconsider exclusions that may not be relevant for people approaching end of life, especially as people approach hospice.
 - e. Equity Fund may consider allocating portions of the fund, so different types of distress have equitable access, and no single category exhausts the entire fund.
 - f. Relying on timeline-based prognostic thresholds can create inequities because someone three years from end of life may experience equal or greater distress than someone one year out.
 - g. A family member or caregiver could qualify for psilocybin therapy, but only if the person they are caring for is also engaged in therapy, but does

tying their eligibility together unintentionally exclude caregivers with legitimate need?

- h. Co-facilitation, group therapy model, group therapy expression
- i. Inclusion of loved ones during preparation and integration for psilocybin therapy for the EOL patient
- j. Existential distress of other forms of debilitating or disability versus an end-of-life diagnosis warrant different considerations for psilocybin therapy and also are adopted within the Patient Qualification and Safety Committee as existential distress with any life limiting illness.
- k. Exclusions must be softer for end-of-life care, cost benefit analysis has shifted for EOL patients
- l. EOL Therapy bringing in other family members, spiritual care
- m. How will end of life care help those left behind to deal with the loss of their loved one, consider how those caretakers, family members and loved ones who really struggle with grief may benefit from psychedelic therapy within the Medical Psilocybin Program
- n. Ketamine for family members and loved ones as the survivors of MAiD (Medical Assistance in Dying) Patients.
- o. EOLC is striving in different ways from having no arbitrary time limits to helping families and loved ones through the difficult End-of-Life process
- p. Integrative care for the grieving family members as PTSD

4. Announcements / Update

- Public Comment Process
 - ✓ Written public comments may be submitted to:
medical.psilocybin@doh.nm.gov
 - ✓ Include the committee's name in the subject line.
 - ✓ If referencing open-source documents, such as peer-reviewed journal articles:
 - Do not include the document, only a working - accessible hyperlink;
 - Documents must be sent with context provided (i.e. do not simply send a research article);
 - ✓ The comment must relate to the topics discussed in the meeting.
 - ✓ Documents are limited to no more than 3 pages (letter size) in length and must be in 10-point font or larger.
 - ✓ Please remember to include your full, legal name and any organizational affiliations you may be representing (if any) on the documents.
 - ✓ To be included, please send your comment by 5:00 PM the business day after the meeting.

5. Next Committee Meetings and Advisory Meeting

- June 12, 2026 @ 09:00AM—11:00AM: Research and Continuous Improvement
- June 12, 2026 @ 01:00PM—03:00PM: Training and Education
- June 15, 2026 @ 09:00AM—10:00AM: Dosage, Administration & Clinical Practice
- June 23, 2026 @ 3:00PM—5:00PM: Equity, Access and Cultural Considerations
- June 26, 2026 @ 09:00AM—11:00AM: Advisory Board
- July 10, 2026 @ 01:00PM—03:00PM: End of Life Care

6. Adjournment

- Meeting adjourned at 02:26pm

7. Public Comments submitted via Teams Meeting Chat or by email

- Dr. Lida Fatemi 01:20pm do you see any interactions or decreased effectiveness with rifaximin or lactulose?
- Jennifer Johnson, 1:31pm, This was great, thank you!
- Dr. Lida Fatemi, 1:31pm, great presentation!
- Jamie Beachy, 1:37pm, Regarding the alcohol use question: Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients with Alcohol Use Disorder, Michael P. Bogenschutz, MD1; Stephen Ross, MD1; Snehal Bhatt, MD2 et al
- Dr. Lida Fatemi, 1:37pm, great study!!!
- Jamie Beachy, 1:37pm, 2022
- Lawrence M Leeman, 1:37pm, UNM was one of two sites of alcohol study!
- Jeff Steinborn, 1:49pm, Great job James! Super informative
- Jeff Steinborn, 2:05pm, No doubt you would need to shift funds around as things played out...but it might create a good apportionment and safeguard of all qualified recipients to begin with.
- Ian Dunn, 2:05pm, Yes, EOL changes the cost benefit analysis of any medications. The exclusions should be softer
- Gregory Evans, 2:12pm, I am so ready for when we are able to have that micro-dosing conversation.
- Chris Caldwell, 2:12pm, Love the microdosing idea!
- Gregory Evans, 2:13pm, perhaps the complication of general wellness.... 🤔
- Gregory Evans, 2:26pm, thank you LARRRRYYYYYY!
- Ian Dunn, 2:26pm, Thank you!
- Jamie Beachy, 2:26pm, Thank you Larry!
- Brooke Kaemingk, 2:26pm, Thank you for this wonderful informative meeting and conversation!!
- 2:27pm Mouchet, Jonathan, DOH stopped recording.
- James Brown, 2:40pm, Thank You Dominic
- No email comments for EOLC Committee Meeting received by 5pm on 06.08.26.